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AbstrACt
Objectives and design Guideline- directed medical 
therapy (GDMT) with renin–angiotensin system (RAS) 
inhibitors and beta- blockers has improved survival in 
patients with heart failure with reduced ejection fraction 
(HFrEF). As clinical trials usually do not include very old 
patients, it is unknown whether the results from clinical 
trials are applicable to elderly patients with HF. This study 
was performed to investigate the clinical characteristics 
and treatment strategies for elderly patients with HFrEF in 
a large prospective cohort.
setting The Korean Acute Heart Failure (KorAHF) registry 
consecutively enrolled 5625 patients hospitalised for acute 
HF from 10 tertiary university hospitals in Korea.
Participants In this study, 2045 patients with HFrEF 
who were aged 65 years or older were included from the 
KorAHF registry.
Primary outcome measurement All- cause mortality data 
were obtained from medical records, national insurance 
data or national death records.
results Both beta- blockers and RAS inhibitors were used 
in 892 (43.8%) patients (GDMT group), beta- blockers only 
in 228 (11.1%) patients, RAS inhibitors only in 642 (31.5%) 
patients and neither beta- blockers nor RAS inhibitors in 
283 (13.6%) patients (no GDMT group). With increasing 
age, the GDMT rate decreased, which was mainly 
attributed to the decreased prescription of beta- blockers. 
In multivariate analysis, GDMT was associated with a 53% 
reduced risk of all- cause mortality (HR 0.47, 95% CI 0.39 
to 0.57) compared with no GDMT. Use of beta- blockers 
only (HR 0.57, 95% CI 0.45 to 0.73) and RAS inhibitors only 
(HR 0.58, 95% CI 0.48 to 0.71) was also associated with 
reduced risk. In a subgroup of very elderly patients (aged 
≥80 years), the GDMT group had the lowest mortality.
Conclusions GDMT was associated with reduced 3- 
year all- cause mortality in elderly and very elderly HFrEF 
patients.
trial registration number NCT01389843.
IntrOduCtIOn
Heart failure (HF) is associated with signif-
icant morbidity, mortality and healthcare 
burdens.1 Since the prevalence of HF increases 
with age, the incidence of elderly patients 
with HF has been continuously increasing as 
the ageing population increases.2–4 Elderly 
patients with HF have worsened outcomes: 
they have more comorbidities, functional and 
cognitive impairments and polypharmacy.5–7 
In addition, they are at high risk of rehospital-
isation for HF after hospital discharge.8
Large clinical trials have shown that 
guideline- directed medical therapy (GDMT) 
with renin–angiotensin system (RAS) inhib-
itors and beta- blockers improved survival in 
patients with heart failure with reduced ejec-
tion fraction (HFrEF).9–11 However, many 
elderly patients with HF have been excluded 
from randomised clinical studies due to age, 
comorbidities or functional or cognitive 
impairments, among others.12 Accordingly, 
it is unknown whether the results from clin-
ical trials can be directly applied to elderly 
patients with HF.
Korea is one of the most rapidly ageing soci-
eties. In 2018, it has become an ‘aged society’ 
and will be a ‘super- aged society’ by 2026.13 In 
2017, Korea’s proportion of individuals aged 
≥65 years was 13.8%. Considering that 70% of 
hospitalisations for HF occurred in patients 
aged ≥65 years, a better understating of 
these high- risk patients is critical for proper 
management.14 In this study, we investigated 
the clinical characteristics and treatment 
strategies for elderly patients with HFrEF in a 
large prospective cohort.
strengths and limitations of this study
 ► This was a large prospective cohort study that in-
cluded patients with heart failure with reduced ejec-
tion fraction who were aged 65 years or older.
 ► We obtained all participants’ mortality data from 
medical or national death records.
 ► The registry could not capture all comorbidities in-
cluding functional or cognitive impairments, which 
is an important prognostic factor for elderly patients.
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MethOds
Participants and cohort recruitment
The Korean Acute Heart Failure (KorAHF) registry is a 
prospective multicentre registry designed to reflect the 
real- world clinical data of Korean patients admitted for 
acute HF. The study design and primary results of the 
registry have been published elsewhere.15 16 Patients hospi-
talised for acute HF from 10 tertiary university hospitals 
in Korea were consecutively enrolled from March 2011 to 
February 2014. Briefly, patients with signs or symptoms 
of HF and either lung congestion or objective findings 
of left ventricle systolic dysfunction or structural heart 
disease were eligible for enrolment in this registry. To 
minimise selection bias, we tried to enrol all hospitalised 
patients with acute HF at each hospital. Patients’ baseline 
characteristics, clinical presentation, underlying diseases, 
vital signs, laboratory tests, treatments and outcomes 
were recorded at admission, and discharge, and during 
follow- up (30 days, 90 days, 180 days and 1–3 years annu-
ally). The mortality data for patients who were lost to 
follow- up were obtained from the national insurance data 
or national death records.
In this study, we included patients with HFrEF who were 
aged 65 years or older. For patient selection, we serially 
excluded patients if any of the exclusion criteria was met. 
Written informed consent was waived by the institutional 
review board. The study complied with the Declaration 
of Helsinki.
Patients and public involvement
Patients were not involved in the conception, design or 
interpretation of this study. The results of this study will 
be disseminated to patients and healthcare providers 
through oral presentations and social media.
study variables and definition
HFrEF was defined as a left ventricular ejection fraction 
(LVEF) of ≤40%. The patients were classified into groups 
according to the medication prescribed at discharge: the 
GDMT group (patients who received both beta- blockers 
and RAS inhibitors), beta- blockers only group, RAS inhib-
itors only group and no GDMT group (no beta- blockers 
or RAS inhibitors). Chronic kidney disease (CKD) 
was defined as a glomerular filtration rate of <60 mL/
min/1.73 m2, and chronic obstructive pulmonary disease 
(COPD) was defined as a self- reported or physician- 
confirmed diagnosis of chronic bronchitis, emphysema 
or both. The primary outcome was 3- year postdischarge 
all- cause mortality from index admission.
statistical analysis
Continuous variables were presented as a mean±SD, 
whereas categorical variables were presented as counts 
and their percentages. Differences among continuous 
variables were analysed using a one- way analysis of vari-
ance and those among categorical variables using the χ2 
test. Logistic regression analysis was used to determine the 
predictors of GDMT prescription. We converted the ORs 
from logistic regression analysis into risk ratios because of 
the high prevalence of GDMT.17 The cumulative event rate 
was assessed using the Kaplan- Meier method with log- rank 
analysis. Multivariable Cox regression analysis was used to 
evaluate the adjusted relative risk of the variables. Multi-
variable models including age, sex, hypertension, diabetes, 
previous HF history, atrial fibrillation, CKD, cause of HF, 
COPD, treatment strategy (no GDMT, beta- blockers only, 
RAS inhibitors only and GDMT) and prescription of miner-
alocorticoid receptor antagonists (MRA), digitalis and 
diuretics were chosen according to their clinical relevance 
and based on the results of previous trials.3 11 Furthermore, 
we performed a prespecified subgroup analysis including 
age, CKD, COPD, HF aetiology and HF onset and produced 
forest plots of the HR of medical therapy (ie, GDMT, beta- 
blockers only and RAS inhibitors only) compared with no 
GDMT. We evaluated whether there was an interaction 
between treatment strategy and the subgroups on all- cause 
mortality. For the calculation of P for interaction, Cox 
regression models were used that included the indicator 
variables for treatment strategy, subgrouping variables and 
interaction term of the treatment strategy- by- subgrouping 
variable of interest (age, CKD, COPD, HF aetiology or HF 
onset), as independent variables. The following covariates 
were also included in the interaction models: sex, hyper-
tension, diabetes, atrial fibrillation and prescription of 
MRA, digitalis and diuretics. To mitigate the impact of 
potential confounding factors in the registry data, we addi-
tionally performed the inverse probability of treatment 
weighting (IPTW). The inferences regarding the rate of 
all- cause death were conducted with robust SEs after exam-
ining covariate balances among treatment groups. We used 
the ‘Twang’ package for R programming for IPTW anal-
ysis. Success of IPTW analyses was assessed by calculating 
the standardised differences in baseline characteristics. All 
statistical analyses were performed using SPSS V.24.0 for 
Windows and R V.3.1.0 (The R Foundation for Statistical 
Computing, Vienna, Austria). A p value <0.05 was consid-
ered statistically significant.
results
The KorAHF registry includes 5625 patients with acute 
HF. Of these, we excluded patients with missing LVEF 
(n=253), those with LVEF >40% (n=1900),<65 years in 
age (n=1268), in- hospital death (n=126), heart transplan-
tation (n=8) and those who were hopelessly discharged 
(n=25), leaving a total of 2045 patients available for the 
final analysis (figure 1).
Overall, the mean age was 75.9 years, 54.2% were 
men, 66.7% had hypertension and 42.0% had diabetes 
mellitus. In addition, the mean LVEF was 28.7%±7.4%, 
and the most common cause of HFrEF was ischaemic 
cardiomyopathy (50.5%).
Medication prescription pattern according to patients’ 
characteristics
The beta- blocker prescription rate at discharge was 54.8% 
in all patients and that of RAS inhibitors was 75.0%. 
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Figure 1 Study flow. EF, ejection fraction; HFrEF, heart 
failure with reduced ejection fraction; KorAHF, Korean Acute 
Heart Failure.
Figure 2 Discharge medication profiles. Prescription of beta- blockers, RAS inhibitors (A) and GDMT (B) in elderly patients with 
HFrEF according to age group. GDMT, guideline- directed medical therapy; HFrEF, heart failure with reduced ejection fraction; 
RAS, renin- angiotensin system.
With increasing age, the beta- blocker prescription rate 
decreased (p for trend <0.001), while that of RAS inhibi-
tors remained unchanged (figure 2A).
The baseline characteristics of the study population are 
summarised in table 1. Overall, both beta- blockers and 
RAS inhibitors were used in 892 (43.8%) patients (GDMT 
group), beta- blockers only in 228 (11.1%) patients, RAS 
inhibitors only in 642 (31.5%) patients and neither beta- 
blockers nor RAS inhibitors in 283 (13.6%) patients (no 
GDMT group). The beta- blocker prescription rate was 
lower in patients with COPD (COPD: 45.5% vs no COPD: 
56.2%, p=0.01), whereas the prescription of RAS inhibi-
tors was lower in patients with CKD (CKD: 68.7% vs no 
CKD: 82.2%, p<0.001).
Five hundred and ninety- four patients (29.0%) were 
already taking beta- blockers before index admission; 
among them, 27.1% discontinued beta- blockers during 
index admission and had lower diastolic blood pres-
sure and higher New York Heart Association (NYHA) 
functional class and NT- pro- BNP levels on admission 
compared with those who continued beta- blockers 
(online supplementary table 1). When classifying 
patients according to beta- blocker use (continuation 
(beta- blocker use before and after admission), new 
initiation (new beta- blocker prescription during index 
admission), discontinuation (beta- blocker use before, 
but discontinuation during index admission) and never 
use groups (no beta blocker before and after index 
admission)), there was no difference in survival between 
patient discontinuation and the never use groups, as 
well as between those in continuation and new initia-
tion groups (online supplementary figure 1). Regarding 
RAS inhibitors, 846 patients (41.4%) were already 
taking RAS inhibitors before index admission. Among 
them, 15.5% discontinued RAS inhibitors during index 
admission and had lower eGFR levels and systolic and 
diastolic blood pressure and higher NYHA functional 
class, potassium and NT- pro- BNP levels on admission 
compared with those who continued RAS inhibitors 
(online supplementary table 2). When classifying the 
patients according to RAS inhibitor usage patterns, 
patients who received RAS inhibitors at discharge had 
better outcomes regardless of previous use than those 
who did not receive RAS inhibitors (online supple-
mentary figure 1). With increasing age, the proportion 
of GDMT prescriptions decreased, while that of RAS 
inhibitors only increased (figure 2B). The predictors 
of GDMT prescription compared with any of the other 
three treatment groups included age 65–79 years, hyper-
tension, diabetes, de novo onset of HF and concomitant 
MRA prescription (table 2). Underlying COPD, CKD 
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Age, years 75.0±6.5 76.2±7.2 76.7±7.1 76.7±6.7 <0.001
Men, n (%) 472 (52.9) 115 (50.7) 369 (57.5) 149 (54.0) 0.211
BMI, kg/m2 23.0±3.5 22.6±3.5 22.4±3.4 21.9±3.0 <0.001
Medical history
  Previous heart failure, n (%) 414 (46.4) 136 (59.6) 361 (56.2) 167 (59.0) <0.001
  Hypertension, n (%) 609 (68.3) 162 (71.4) 417 (65.0) 174 (63.0) 0.124
  Diabetes, n (%) 399 (44.7) 97 (42.7) 242 (37.7) 119 (43.1) 0.050
  Chronic kidney disease, n (%) 430 (48.2) 150 (66.1) 320 (49.8) 186 (67.4) <0.001
  Atrial fibrillation, n (%) 281 (31.5) 89 (39.2) 193 (30.1) 81 (29.3) 0.059
  COPD, n (%) 92 (10.3) 30 (13.2) 110 (17.1) 36 (13.0) 0.002
  Myocardial infarction, n (%) 194 (21.8) 61 (26.9) 146 (22.7) 65 (23.6) 0.433
Cause of heart failure
  Ischaemic, n (%) 443 (49.7) 129 (56.8) 311 (48.4) 146 (52.9) 0.132
  Dilated, n (%) 222 (24.9) 36 (15.9) 147 (22.9) 50 (18.1) 0.008
Medication on admission
  Beta- blocker, n (%) 316 (35.4) 117 (51.5) 107 (16.7) 53 (19.2) <0.001
  RAS inhibitor, n (%) 380 (42.6) 58 (25.6) 335 (52.2) 72 (26.1) <0.001
  MRA, n (%) 143 (16.0) 47 (20.7) 122 (19.0) 60 (21.7) 0.096
Medication on discharge         
  MRA, n (%) 487 (54.6) 95 (41.9) 316 (49.2) 120 (43.5) <0.001
  Loop diuretics, n (%) 714 (80.0) 174 (76.7) 493 (76.8) 189 (68.5) 0.001
  Digoxin, n (%) 269 (30.2) 63 (27.8) 193 (30.1) 86 (31.2) 0.865
Systolic BP on discharge, mm Hg 115.0±17.0 115.7±16.4 114.2±16.5 113.0±16.6 0.067
Diastolic BP on discharge, mm Hg 66.1±10.7 67.5±10.7 65.6±11.2 65.2±10.0 0.026
Heart rate on discharge, beats/min 74.6±12.9 78.1±14.4 77.8±14.3 80.6±13.7 <0.001
NYHA functional class on discharge 0.154
  I or II, n (%) 792 (88.8) 205 (90.3) 566 (88.2) 250 (90.6)
  III or IV, n (%) 100 (11.2) 22 (9.7) 76 (11.8) 45 (9.4)
Echocardiographic parameters
  LVEDD, mm 60.3±8.7 57.6±9.6 61.2±8.9 58.8±9.0 <0.001
  LVESD, mm 50.3±9.3 47.6±10.0 51.1±9.6 49.1±9.8 <0.001
  LVEF, % 28.8±7.3 28.8±7.5 28.5±7.4 28.6±7.7 0.864
Laboratory data on admission
  Haemoglobin, g/dL 12.4±2.0 11.9±2.2 12.2±2.1 11.7±2.2 <0.001
  eGFR, mL/min/1.73 m2 63.8±33.8 52.6±32.3 63.2±30.4 53.2±30.1 <0.001
  Sodium, mEq/L 138.0±4.4 137.6±4.4 137.3±5.1 137.0±4.6 0.006
  Potassium, mEq/L 4.3±0.7 4.4±0.7 4.4±0.7 4.5±0.8 0.001
  BNP, pg/mL 1592.9±1489.8 1849.7±1492.0 1724.8±1381.7 1937.1±1920.8 0.223
  NT- pro- BNP, pg/mL 10941.1±11 006.9 11535.8±10 587.7 9978.0±9484.0 14728.7±12 514.7 <0.001
BMI, body mass index; BNP, brain natriuretic peptide; BP, blood pressure; COPD, chronic obstructive pulmonary disease; GDMT, guideline- directed 
medical therapy; GFR, glomerular filtration rate; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left 
ventricular end systolic diameter; MRA, mineralocorticoid receptor antagonist; NT- pro- BNP, N- terminal pro- brain natriuretic peptide; NYHA, New York 
Heart Association; RAS, renin–angiotensin system.
and concomitant use of loop diuretics were inversely 
associated with the prescription of GDMT.
Clinical outcomes
The median follow- up duration was 833 days (IQR: 
240.5–1095 days), and 866 (42.3%) patients had died at 
3 years. In the Kaplan- Meier survival analysis, patients in 
the GDMT group had the lowest mortality, whereas those 
in the no GDMT group had the worst outcomes. Inter-
estingly, there seemed to be no difference in mortality 
between the beta- blockers only and RAS inhibitors only 
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Table 2 Predictors of prescription of guideline- directed 
medical therapy compared with any of the other three 
treatment groups
Variable Risk ratio 95% CI P value
Age 65–79 (vs age ≥80) 
years
1.28 1.14 to 1.43 <0.001
Male 0.94 0.85 to 1.04 0.240
Hypertension 1.13 1.01 to 1.25 0.036
Diabetes 1.14 1.03 to 1.26 0.014
De novo heart failure (vs 
previous heart failure)
1.28 1.16 to 1.40 <0.001
Atrial fibrillation 1.01 0.89 to 1.13 0.911
Chronic kidney disease 0.86 0.77 to 0.96 0.004
Ischaemic CMP (vs non- 
ischaemic)
0.97 0.86 to 1.07 0.546
COPD 0.79 0.65 to 0.93 0.004
Discharge MRA 1.16 1.05 to 1.28 0.007
Discharge digoxin 0.97 0.86 to 1.09 0.634
Discharge loop diuretics 0.84 0.72 to 0.98 0.018
CMP, cardiomyopathy; COPD, chronic obstructive pulmonary 
disease; MRA, mineralocorticoid receptor antagonist.
Figure 3 Three- year cumulative survival according to the treatment groups. Patients receiving GDMT had lower mortality 
among all patients (A), patients aged between 65 years and 79 years (B) and patients aged 80 years or older (C). BB, beta- 
blocker; GDMT, guideline- directed medical therapy; RASi, renin–angiotensin system inhibitor.
Table 3 Multivariable Cox regression analysis for all- cause 
mortality
Variable HR 95% CI P value
Age ≥80 (vs age 65–79) 
years
1.60 1.39 to 1.84 <0.001
Male 1.16 1.01 to 1.33 0.039
Hypertension 1.07 0.92 to 1.24 0.392
Diabetes 1.13 0.99 to 1.31 0.080
Previous heart failure (vs 
de novo heart failure)
1.39 1.20 to 1.60 <0.001
Atrial fibrillation 0.90 0.77 to 1.07 0.226
Chronic kidney disease 1.50 1.30 to 1.74 <0.001
Ischaemic CMP (vs non- 
ischaemic)
1.29 1.11 to 1.49 <0.001
COPD 1.27 1.04 to 1.53 0.016
Discharge MRA 1.05 0.91 to 1.21 0.499
Discharge digoxin 0.99 0.84 to 1.16 0.885
Discharge loop diuretics 0.90 0.76 to 1.06 0.219
Treatment strategy (vs no GDMT)
  Beta- blocker only 0.57 0.45 to 0.73 <0.001
  RAS inhibitor only 0.58 0.48 to 0.71 <0.001
  GDMT 0.47 0.39 to 0.57 <0.001
CMP, cardiomyopathy; COPD, chronic obstructive pulmonary 
disease; GDMT, guideline- directed medical therapy; MRA, 
mineralocorticoid receptor antagonist; RAS, renin–angiotensin 
system.
groups (figure 3). On further stratification of the patients 
according to age above or below 80 years, the GDMT 
group had the lowest mortality in patients aged above and 
below 80 years, consistently. In IPTW adjusted population 
patients in the GDMT group had lower mortality than 
those in the no GDMT group among the overall patients, 
patients aged between 65 years and 69 years, and patients 
aged 80 years or older (online supplementary table 
3, online supplementary figure 2). In the Cox model 
after adjustment for significant covariates, GDMT was 
associated with a 53% reduced risk of all- cause mortality 
(HR 0.47, 95% CI 0.39 to 0.57, p<0.001) compared with 
no GDMT. The beta- blockers (HR 0.57, 95% CI 0.45 to 
0.73, p<0.001) or RAS inhibitors (HR 0.58, 95% CI 0.48 
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Figure 4 Subgroup analysis. The HRs of medical therapy (ie, GDMT, beta- blockers only and RAS inhibitors only) compared 
with no GDMT for all- cause mortality in subgroups were calculated using multivariate Cox regression analysis. The forest plots 
demonstrate the HRs of GDMT versus no GDMT from the results. There was no significant interaction between the treatment 
strategy (no GDMT, beta- blockers only, RAS inhibitors only and GDMT) and diverse subgroups, and GDMT was associated with 
lower morality across subgroups. *The p for interaction indicates whether treatment strategy interacts with the subgrouping 
variable. It was calculated from multivariable Cox regression analysis that included the variables for treatment strategy, 
subgrouping variables, interaction term of the treatment strategy- by- subgrouping variable, sex, hypertension, diabetes, atrial 
fibrillation and prescription of mineralocorticoid receptor antagonists, digitalis and diuretics. CKD, chronic kidney disease; 
COPD, chronic obstructive pulmonary disease; HF, heart failure; GDMT, guideline- directed medical therapy; RAS, renin–
angiotensin system.
to 0.71, p<0.001) only groups were also associated with 
reduced risk (table 3).
subgroup analysis
We performed a prespecified subgroup analysis according 
to age (65–79 years vs ≥80 years), CKD, COPD, aetiology 
(ischaemic vs non- ischaemic) and HF onset (de novo HF 
vs acute decompensation of chronic HF). There was no 
significant interaction between medical therapy and any 
subgroup (figure 4).
dIsCussIOn
The present nationwide multicentre prospective cohort 
study showed: (1) GDMT was associated with reduced 
all- cause mortality in elderly patients with HFrEF; (2) 
prescription of beta- blockers or RAS inhibitors only was 
also associated with reduced all- cause mortality compared 
with no GDMT; and (3) the effect of GDMT also appeared 
to be effective for reducing all- cause mortality in very 
elderly patients (age ≥80 years).
GdMt and outcomes in elderly patients with hF
Large clinical trials have shown the efficacy of GDMT in 
patients with HFrEF.11 However, the patients enrolled 
in such clinical trials were younger and had fewer 
comorbidities than real- world elderly patients.18 More-
over, data from clinical trials supporting the use of GDMT 
in elderly patients are scarce. The Study of the Effects of 
Nebivolol Intervention on Outcomes and Rehospitalisa-
tion in Seniors with Heart Failure (SENIORS) study, which 
included 2128 patients aged ≥70 years with a history of 
HF, is considered the representative study conducted in 
elderly patients with HF. It showed that nebivolol reduced 
the composite of all- cause mortality and rehospitalisation 
for HF but did not reduce all- cause mortality.19
Although observational studies do not provide as high 
a level of evidence as randomised clinical trials, they may 
yield real- world evidence.20 21 In previous observational 
studies, the efficacy of beta- blockers in elderly patients 
has been controversial. In the Organized Program to 
Initiate Lifesaving Treatment in Hospitalized Patients with 
Heart Failure (OPTIMIZE- HF) registry, a beta- blocker 
was not associated with improved survival in patients 
aged ≥75 years.20 Dobre et al22 reported that the effect 
of beta- blockers decreased with increasing age and was 
not associated with a reduced risk of cardiac death and 
readmission HF in patients aged ≥80 years.22 Recently, 
in a subgroup of 237 elderly patients aged ≥80 years in 
the West Tokyo Heart Failure (WET- HF) registry, GDMT 
with beta- blockers and RAS inhibitors did not reduce the 
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rates of cardiac death or HF readmission.23 By contrast, 
the present study showed that GDMT was associated with 
all- cause mortality in elderly (≥65 years) patients with 
HFrEF. In addition, GDMT was effective in very elderly 
patients (≥80 years). Although the KorAHF and WET- HF 
studies have included East Asian patients with HF, there 
are several differences between the studies: KorAHF was 
larger, especially in terms of the number of patients aged 
≥80 years (601 patients in KorAHF vs 237 patients in 
WET- HF). As a result, our study was less prone to type 
II errors, such as false negative findings. While WET- HF 
defined HFrEF as LVEF <45%, the present study enrolled 
only patients with LVEF ≤40%, which corresponds to the 
contemporary definition of HFrEF.11 To our knowledge, 
this is the first report to show the efficacy of GDMT in 
very elderly patients with HFrEF.
Prescription of GdMt in elderly patients
The prescription rate of GDMT was 50% in patients 
aged 65–69 years and 30% in those aged ≥85 years. The 
decline can be mainly attributed to a decreasing beta- 
blocker prescription rate. Hamaguchi et al24 reported 
that the prescription rate of beta- blockers was 48% in 
HFrEF patients aged ≥80 years and that GDMT was 
applied only in 38% of these patients.24 In this study, the 
beta- blocker prescription rate was 55% in all patients 
and 46% in patients aged ≥80 years. Beta- blockers in 
very elderly patients may be withheld due to the poten-
tial side effects and uncertainty with regard to the bene-
fits for this high- risk group. In addition, 13% of patients 
had COPD, which was associated with a 30% reduced 
prescription rate of beta- blockers (beta- blockers in 
COPD 46% vs no COPD 56%, p<0.001) but not of RAS 
inhibitors. Accordingly, COPD was associated with a 
33% reduced prescription rate of GDMT. This finding 
reflects the possible side effect of beta- blockers, as non- 
selective beta- blockers may cause bronchoconstriction 
in patients with COPD. However, given that multiple 
studies have shown that beta-1 selective beta- blockers 
can be used safely in patients with asthma and COPD, 
beta-1 selective drugs should be considered for patients 
with COPD.25 26
CKD is very common in patients with HF and is a well- 
known risk factor in patients with HF.24 27 In this study, 
53% of patients had CKD, and its prevalence increased 
with age. Since RAS inhibitors can initially aggravate 
renal function, many physicians withhold RAS inhibitors 
in patients with CKD. Accordingly, CKD was associated 
with a 54% reduced prescription rate of RAS inhibitors 
(RAS inhibitors in CKD: 68% vs no CKD: 83%, p<0.001), 
resulting in a 24% reduced prescription rate of GDMT. 
By contrast, beta- blocker usage was not influenced by the 
presence of CKD. Current guidelines recommend the 
cautious use of RAS inhibitors in patients with HF and 
advanced CKD.11 Our study supports this recommenda-
tion, since RAS inhibitor use was associated with a 34% 
reduced risk of all- cause mortality in patients with CKD.
limitations
The present study has several limitations. First, owing to 
the observational nature of the study design, confounding 
factors may have influenced the study results, despite 
adjustment for significant covariates. Furthermore, there 
exists a possibility that unmeasured variables may have 
influenced the results. Second, the registry could not 
capture all comorbidities including functional or cogni-
tive impairments, which are an important prognostic 
factor for elderly patients.28 Third, we performed the 
IPTW analysis to mitigate the impact of compounding 
factors, but there exists the possibility that variables 
included in the IPTW analysis had not been sufficiently 
categorised for producing balanced groups. Fourth, 
although the KorAHF registry was designed to enrol all 
hospitalised patients with HF, there exists the possibility 
that some of the patients may not have been enrolled. 
Fourth, we did not consider the dosage when defining 
GDMT. Although there exists controversy on the relation-
ship between drug dosage and outcomes, it should also 
be investigated in elderly patients.29 Finally, we do not 
know whether the patients actually took the prescribed 
drugs, as many patients had multiple comorbidities, and 
polypharmacy is known to be associated with poor drug 
compliance.
COnClusIOns
HF is common among the elderly, but elderly patients 
with HF receive less GDMT. The present study suggests 
that GDMT may be effective in elderly and very elderly 
patients with HFrEF, and physicians should make an 
effort to prescribe GDMT to these high- risk patients.
Author affiliations
1Division of Cardiology, Department of Internal Medicine, Kangdong Sacred Heart 
Hospital, Hallym University College of Medicine, Seoul, Republic of Korea
2Cardiovascular Center, Division of Cardiology, Seoul National University Bundang 
Hospital, Seongnam, Republic of Korea
3Department of Family Medicine, Inje University Seoul Paik Hospital, Seoul, Republic 
of Korea
4Department of Internal Medicine, Seoul National University Hospital, Seoul, 
Republic of Korea
5Department of Cardiology, Chonnam National University Hospital, Gwangju, 
Republic of Korea
6Department of Internal Medicine, Yonsei University Wonju College of Medicine, 
Wonju, Republic of Korea
7Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College 
of Medicine, Seoul, Republic of Korea
8Division of Cardiology, Department of Internal Medicine, The Catholic University of 
Korea, Seoul, Republic of Korea
9Department of Internal Medicine, Sungkyunkwan University College of Medicine, 
Seoul, Republic of Korea
10Department of Cardiology, Asan Medical Center, Seoul, Republic of Korea
11Department of Internal Medicine, Chungbuk National University College of 
Medicine, Cheongju, Republic of Korea
12Department of Internal Medicine, Kyungpook National University College of 
Medicine, Daegu, Republic of Korea
13Mediplex Sejong Hospital, Incheon, Republic of Korea
Contributors W- WS, JJP and D- JC: substantial contributions to the conception or 
design of the work, acquisition, analysis and interpretation of data. HAP, H- JC, H- YL, 
8 Seo W- W, et al. BMJ Open 2020;10:e030514. doi:10.1136/bmjopen-2019-030514
Open access 
KKH, B- SY, S- MK, SHB, E- SJ, J- JK, M- CC, SCC and B- HO: substantial contributions 
to the conception or design of the work and acquisition of data.
Funding This work was supported by Research of Korea Centers for Disease 
Control and Prevention (2010- E63003-00, 2011- E63002-00, 2012- E63005-00, 
2013- E63003-00, 2013- E63003-01, 2013- E63003-02 and 2016- ER6303-00) and 
by the SNUBH Research Fund (Grant no 14-2015-029 and 16-2017-003).
Competing interests None declared.
Patient consent for publication Not required.
ethics approval The study protocol was approved by the ethics committee 
at each participating tertiary university hospital in Korea (Institutional Review 
Board (IRB) of Seoul National University Bundang Hospital, IRB number B1104 
125 014; IRB of Seoul National University Hospital, IRB number 1102-072-352; 
IRB of Yonsei University Severance Hospital, IRB number 4-2011-0075; IRB of 
Kyungpook National University Hospital, IRB number 2011-04-016; IRB of Asan 
Medical Center, IRB number 2011-0204; IRB of Seoul St Mary’s Hospital, IRB 
number KC110IMI0172; IRB of Chonnam National University Hospital, IRB number 
CHUN-2011-061; IRB of Chungbuk National University Hospital, IRB number 2011-
03-008; IRB of Samsung Medical Center, IRB number 2013-040017; IRB of Wonju 
Severance Christian Hospital, IRB number CR311003).
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement Data are housed at the Research of Korea Centers for 
Disease Control and Prevention and are available on reasonable request.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
OrCId ids
Hyun- Jai Cho http:// orcid. org/ 0000- 0002- 2779- 4037
Seok- Min Kang http:// orcid. org/ 0000- 0001- 9856- 9227
Myeong- Chan Cho http:// orcid. org/ 0000- 0002- 0047- 0227
Dong- Ju Choi http:// orcid. org/ 0000- 0003- 0146- 2189
reFerenCes
 1 Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact 
of heart failure in the United States: a policy statement from the 
American heart association. Circ Heart Fail 2013;6:606–19.
 2 Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of 
heart failure; a population- based study. Eur Heart J 1999;20:421–8.
 3 Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset 
of congestive heart failure in Framingham heart study subjects. 
Circulation 1993;88:107–15.
 4 Youn J- C, Han S, Ryu K- H. Temporal trends of hospitalized patients 
with heart failure in Korea. Korean Circ J 2017;47:16–24.
 5 Murad K, Goff DC, Morgan TM, et al. Burden of comorbidities and 
functional and cognitive impairments in elderly patients at the initial 
diagnosis of heart failure and their impact on total mortality: the 
cardiovascular health study. JACC Heart Fail 2015;3:542–50.
 6 Shah RU, Tsai V, Klein L, et al. Characteristics and outcomes of very 
elderly patients after first hospitalization for heart failure. Circ Heart 
Fail 2011;4:301–7.
 7 Vidán MT, Blaya- Novakova V, Sánchez E, et al. Prevalence and 
prognostic impact of frailty and its components in non- dependent 
elderly patients with heart failure. Eur J Heart Fail 2016;18:869–75.
 8 Krumholz HMet al. Readmission after hospitalization for congestive 
heart failure among Medicare beneficiaries. Arch Intern Med 
1997;157:99–104.
 9 Effect of enalapril on mortality and the development of heart failure 
in asymptomatic patients with reduced left ventricular ejection 
fractions. N Engl J Med 1992;327:685–91.
 10 Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol 
on survival in severe chronic heart failure. N Engl J Med 
2001;344:1651–8.
 11 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the 
diagnosis and treatment of acute and chronic heart failure: The Task 
Force for the diagnosis and treatment of acute and chronic heart 
failure of the European Society of Cardiology (ESC)Developed with 
the special contribution of the Heart Failure Association (HFA) of the 
ESC. Eur Heart J 2016;37:2129–200.
 12 Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older 
patients from ongoing clinical trials regarding heart failure. Arch 
Intern Med 2011;171:550–6.
 13 Statistics Korea, 2017. Available: http:// kostat. go. kr/ portal/ eng/ 
pressReleases/ 11/ 1/ index. board? bmode= download& bSeq=& aSeq= 
363974& ord=1
 14 Hall MJ, Levant S, DeFrances CJ. Hospitalization for congestive 
heart failure: United States, 2000–2010. NCHS data brief. Available: 
https://www. cdc. gov/ nchs/ data/ databriefs/ db108. pdf
 15 Lee SE, Cho H- J, Lee H- Y, et al. A multicentre cohort study of acute 
heart failure syndromes in Korea: rationale, design, and interim 
observations of the Korean acute heart failure (KorAHF) registry. Eur 
J Heart Fail 2014;16:700–8.
 16 Lee SE, Lee H- Y, Cho H- J, et al. Clinical characteristics and outcome 
of acute heart failure in Korea: results from the Korean acute heart 
failure registry (KorAHF). Korean Circ J 2017;47:341–53.
 17 Zhang J, Yu KF. What's the relative risk? A method of correcting 
the odds ratio in cohort studies of common outcomes. JAMA 
1998;280:1690–1.
 18 Heiat A, Gross CP, Krumholz HM. Representation of the elderly, 
women, and minorities in heart failure clinical trials. Arch Intern Med 
2002;162:1682–8.
 19 Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to 
determine the effect of nebivolol on mortality and cardiovascular 
hospital admission in elderly patients with heart failure (seniors). Eur 
Heart J 2005;26:215–25.
 20 Hernandez AF, Hammill BG, O'Connor CM, et al. Clinical 
effectiveness of beta- blockers in heart failure: findings from the 
OPTIMIZE- HF (organized program to initiate lifesaving treatment in 
hospitalized patients with heart failure) registry. J Am Coll Cardiol 
2009;53:184–92.
 21 Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence- based 
care for heart failure in outpatient cardiology practices: primary 
results of the registry to improve the use of evidence- based heart 
failure therapies in the outpatient setting (improve HF). Circulation 
2010;122:585–96.
 22 Dobre D, DeJongste MJL, Lucas C, et al. Effectiveness of ?-blocker 
therapy in daily practice patients with advanced chronic heart 
failure; is there an effect- modification by age? Br J Clin Pharmacol 
2007;63:356–64.
 23 Akita K, Kohno T, Kohsaka S, et al. Current use of guideline- based 
medical therapy in elderly patients admitted with acute heart failure 
with reduced ejection fraction and its impact on event- free survival. 
Int J Cardiol 2017;235:162–8.
 24 Hamaguchi S, Kinugawa S, Goto D, et al. Predictors of long- term 
adverse outcomes in elderly patients over 80 years hospitalized with 
heart failure. Circ J 2011;75:2403–10.
 25 Salpeter S, Ormiston T, Salpeter E. Cardioselective beta- blocker use 
in patients with reversible airway disease. Cochrane Database Syst 
Rev 2002:CD002992.
 26 Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective 
β-blockers in patients with reactive airway disease. Ann Intern Med 
2002;137:715–25.
 27 Komajda M, Hanon O, Hochadel M, et al. Contemporary 
management of octogenarians hospitalized for heart failure in 
Europe: Euro heart failure survey II. Eur Heart J 2008;30:478–86.
 28 Murad K, Goff DC, Morgan TM, et al. Burden of Comorbidities and 
Functional and Cognitive Impairments in Elderly Patients at the Initial 
Diagnosis of Heart Failure and Their Impact on Total Mortality. JACC 
Heart Fail 2015;3:542–50.
 29 Turgeon RD, Kolber MR, Loewen P, et al. Higher versus lower doses 
of ACE inhibitors, angiotensin-2 receptor blockers and beta- blockers 
in heart failure with reduced ejection fraction: systematic review and 
meta- analysis. PLoS One 2019;14:e0212907.
